The European Commission authorised the world’s first single-shot mRNA vaccine against both COVID-19 and flu. America can’t even get the flu component approved.
On 21 April 2026, the European Commission granted full marketing authorisation for mCOMBRIAX — Moderna‘s mRNA combination vaccine against both influenza and COVID-19. The authorisation covers all 27 European Union member states, plus Iceland, Liechtenstein, and Norway. It is the first regulatory approval anywhere in the world for a vaccine protecting against both respiratory viruses in a single dose. Moderna calls it mCOMBRIAX. Scientists know it as mRNA-1083. Anyone over 50 in Europe will soon know it as the one jab that does the job of two.
The timing carries a sting. At the same moment Europe approved mCOMBRIAX, the US Food and Drug Administration (FDA) had not just failed to approve the combination vaccine — it had refused even to review the standalone flu component the combination product is built on. That regulatory divergence is not a footnote. It is the story.
What’s Happening & Why It Matters
What mCOMBRIAX Is and How It Works
mCOMBRIAX is a single-dose mRNA vaccine. It targets four separate pathogens in one shot — three influenza strains (A/H1N1, A/H3N2, and B/Victoria) plus SARS-CoV-2. The vaccine combines the technology behind two of Moderna‘s existing products: mNexspike (its COVID-19 vaccine) and mRNA-1010 (its investigational influenza vaccine). Both use the same mRNA delivery platform. Combining them into a single product does not require a fundamentally new manufacturing process — it leverages a platform Moderna has built and refined since 2020.
The authorisation targets adults aged 50 and older. That focus is deliberate. Both COVID-19 and seasonal influenza cause disproportionately severe illness in older adults. Each year, influenza causes between 15,000 and 70,000 deaths across the European Economic Area alone. COVID-19 has caused nearly 282 million cases across Europe since the pandemic began. The two diseases together represent the most significant preventable respiratory burden on healthcare systems in the developed world — particularly for older populations.
What the Phase 3 Trial Showed
The European Medicines Agency (EMA)‘s positive opinion — issued on 27 February 2026 and ratified by the European Commission on 21 April — followed a rigorous review of a Phase 3 clinical trial. The trial enrolled approximately 8,000 participants aged 50 and older across two independent cohorts of around 4,000 participants each.
The first cohort covered adults aged 65 and older. Researchers compared mCOMBRIAX against co-administered Fluzone HD — a high-dose influenza vaccine used preferentially for older adults — and Spikevax, Moderna‘s licensed COVID-19 vaccine. The second cohort covered adults aged 50 to 64. That group received either mCOMBRIAX or co-administered Fluarix (a standard-dose flu vaccine) and Spikevax.
The results cleared every primary endpoint. After a single dose, mCOMBRIAX produced immune responses that were non-inferior to those of both comparator regimens. In both age groups, the vaccine generated statistically significantly higher antibody responses against all three influenza strains tested. No major safety concerns or unexpected adverse events were observed in the trial data. Moderna CEO Stéphane Bancel described the outcome plainly. “We welcome the European Commission’s approval of mCOMBRIAX, the world’s first flu plus COVID-19 combination vaccine,” he said. “Combination vaccines have the potential to simplify vaccination and support improved health outcomes.”
Why Simplifying Vaccination Matters
The practical case for a combination vaccine is straightforward. Annual flu vaccination rates in most countries hover between 30% and 60% for eligible adults. COVID-19 booster uptake has declined steeply since 2022. A vaccine that protects against both diseases with a single appointment removes a meaningful logistical barrier. Patients who might skip one shot are more likely to show up for a single annual jab that covers two major respiratory threats.
For healthcare systems, the efficiency gains compound quickly. Pharmacies and GP surgeries delivering seasonal vaccinations at scale face a significant administrative burden running two separate campaigns. A single combination product reduces appointment volumes, simplifies storage complexity, and streamlines patient communication. At the population scale, even a modest improvement in uptake translates into materially fewer hospitalisations and fewer deaths. That is the public health case for mCOMBRIAX — and it is a strong one.
The US Regulatory Disaster
The contrast with the United States is striking. Moderna first submitted a Biologic License Application to the FDA for mCOMBRIAX in 2024. The FDA requested additional data on the flu component. Moderna withdrew the combination vaccine application and decided to seek standalone approval for the flu component — mRNA-1010 — first. That approach seemed logical. Get the flu vaccine approved, then resubmit the combination.
On 10 February 2026, the FDA issued a “refuse-to-file” letter for mRNA-1010 — the standalone flu vaccine that underpins mCOMBRIAX. The agency stated the application was not adequately controlled because Moderna had chosen the wrong comparator vaccine in its Phase 3 trial. FDA Centre Director Vinay Prasad signed the letter. A “refuse-to-file” decision is extremely rare — only about 4% of FDA applications receive one.
The decision shocked the industry for two reasons. First, the FDA had previously provided written guidance in April 2024 stating that using a standard-dose flu vaccine as a comparator was acceptable. Moderna followed that guidance. The agency then changed its position after the application arrived. Second, three sources with knowledge of internal FDA deliberations told STAT News that career scientists had recommended proceeding with the review. Prasad overruled them. His letter cited no safety or efficacy concerns whatsoever.
The Political Context Behind the FDA Blockade
The regulatory environment at the FDA has shifted dramatically under the Trump administration. Robert F. Kennedy Jr., the Secretary of Health and Human Services, has long expressed scepticism of vaccine programmes — including mRNA technology specifically. Under Kennedy’s oversight, the FDA has applied unusually strict scrutiny to mRNA vaccine applications. Moderna is the most visible target of that scrutiny.
Moderna responded publicly to the FDA’s refusal by posting Prasad’s letter online — an unusual step that signals genuine frustration with the regulatory process. The company described the rationale as “inconsistent” with prior written guidance. It has since requested a Type A meeting with the FDA to understand what path, if any, exists toward eventual approval. A Type A meeting is typically reserved for situations where a clinical programme has encountered a serious problem.
In response to the controversy, Moderna announced it would no longer invest in new late-stage vaccine trials in the United States. The company is refocusing its clinical investment toward cancer vaccines and other therapeutic areas with a more predictable regulatory environment. That decision has long-term public health implications that extend well beyond mCOMBRIAX.
Where mCOMBRIAX Goes From Here in Europe
The European Commission’s authorisation is valid across all 30 markets — 27 EU member states plus the three EEA countries. Each country’s health authority determines how to implement the vaccine in its national programme. That process involves reimbursement decisions, procurement negotiations, and updates to clinical guidance. Moderna is working with national authorities across Europe to support access and implementation. The company is targeting the 2026 autumn respiratory vaccination season as the first opportunity for widespread deployment.
The vaccine’s commercial significance to Moderna is substantial. COVID-19 vaccine sales have declined sharply since the pandemic peak. RSV vaccine contributions are minimal. mCOMBRIAX represents Moderna‘s most credible new revenue stream in the near term — though the company had specifically excluded any 2026 revenue from the combination vaccine in its financial forecasts. The EU approval means those projections have meaningful upside potential for H2 2026.
TF Summary: What’s Next
Moderna is now working with national health authorities across Europe to secure pricing, reimbursement, and procurement agreements. Deployment at scale depends on those national-level processes moving quickly enough to reach the autumn 2026 vaccination window. Canada and Australia also have mRNA-1010 — the standalone flu component — under regulatory review, suggesting additional approvals could follow the EU’s lead before year-end.
MY FORECAST: In the United States, the path forward is unclear. Moderna‘s requested Type A meeting with the FDA will determine whether refiling the mRNA-1010 application is viable — and on what basis. Unless that process resolves in the near term, mCOMBRIAX will not reach American patients during the 2026 autumn season. The regulatory divergence between Europe and the US on mRNA vaccines has concrete, measurable consequences. European adults over 50 can receive a single shot protecting against both COVID-19 and influenza this autumn. Their American counterparts cannot. That gap — between a continent that evaluated the science and acted on it, and a federal agency that overruled its own scientists on procedural grounds — is the most important story in vaccine policy this year.